Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Impact of Isolation in Patients With IBD During the COVID-19 Crisis

27 de julho de 2020 atualizado por: Sheffield Teaching Hospitals NHS Foundation Trust

Impact of Isolation in Patients With IBD During the 2020 COVID-19 Crisis: a Mixed Methods Study

The coronavirus pandemic has changed healthcare dramatically in a short time. Individuals with chronic illnesses and services for them have had to adapt and change to deal with requirements for shielding and social isolation to reduce infection risk and management of medication investigation and ongoing review.

It is increasingly recognised that the pandemic and the changes to daily life will have had a series of impacts on patients and health care services, including impacts on patients psychological well-being and the opportunity to seek medical care for non-CoViD illness.

Psychological symptoms such as depression, anxiety and hopelessness is well described in adults and young people with inflammatory bowel disease. Quarantine has also been associated with these psychological symptoms and also post-traumatic stress. It is important to identify the extent of and factors that influence negative psychological consequences of isolation in patients with inflammatory bowel disease.

This study will aim to assess what impact the isolation of patients during social isolation had in terms of psychological well-being - and what are the factors affecting this impact, particularly in younger and old age groups.

Visão geral do estudo

Status

Desconhecido

Descrição detalhada

This study will use both questionnaires and semi-structured interviews to understand how IBD patients have been impacted psychologically by the CoViD-19 pandemic and identify various factors that may affect the extent to which patients have been impacted. This study will also incorporate longitudinal questionnaire follow-up of the same patients, in order to try and understand the long-term impact of the pandemic, and to assess changes in psychological impact accompanying changes in the national situation.

Patients identified from those attending the IBD clinic will be contacted. As part of the NHSE and local Trust CoViD response, lists of all patients attending the IBD clinics and those deemed to be at high risk of infection have been created.

This study aims to recruit 100 patients from the high-risk group and 100 patients from the non-high-risk group. Basedon an approximately 33% response rate, we have therefore elected to identify 300 patients from the high-risk groups and 300 from non-high-risk groups. These 600 patients in total will be contacted via the post, and mailed:

  1. An explanatory cover letter, with instructions on how to participate in the study
  2. Participant information sheet (PIS)
  3. Consent form
  4. Questionnaires
  5. A stamped and addressed return envelope

Completion of questionnaire and return to site will constitute as consent for this data to be used. Postal recruitment is being used to maximise the chances of reaching those who may have been most affected by isolation and may have limited access to the internet. The consent form will apply to the optional interview component.

The PIS will include information signposting patients to help and support should they have difficulties or concerns relating to the study or the psychological impact of their condition or current situation.

Record of who has been contacted to participate will be kept on NHS computers, with patient hospital numbers corresponding to anonymous and non-identifiable study identification numbers. Keeping record will permit there to be available data regarding the questionnaire return rate. This will also potentially allow for demographic details to be retrieved from patient records regarding those who did not return responses, to facilitate both assessment of differences between responders and non-responders and provide information about those who elected not to participate.

In addition, a sub-set of 32 young people will be contacted and recruited. This sub-set have already undertaken the assessment of psychological morbidity, outlined below, during a previous, pre-CoViD outbreak study (STH20960 IRAS: 269881) and have agreed to further follow-up. These patients will also be contacted via the post to complete the same set of questionnaires and therefore provide follow-up, to assess whether measures of psychological morbidity changed following the onset of the CoViD crisis.

Patients will be asked to complete the following questionnaires:

  1. IBD symptoms: IBD control questionnaire
  2. Experience during the CoViD periods of isolation
  3. Impact of event scale (iES-15 questionnaire)
  4. Depression Anxiety Stress Scale-21 (DASS-21)

Background information, as listed below, will be collected in order to try and identify demographic and disease related details which may affect the level of psychological impact for IBD patients:

  1. Age
  2. Ethnicity
  3. Postcode (used to calculate indices of deprivation scores, using the Indices of Multiple Deprivation [IMD] tool)
  4. Disease type
  5. Medication
  6. BSG risk group

The same patients will be contacted and asked to complete the questionnaires again after 6 and 12 months to assess changes in psychological impact and relationship to societal requirements for isolation.

Semi structured interviews will be undertaken with approximately 20 participants. More may be undertaken until saturation point is reached.

Semi-structured interviews will be undertaken to provide further detail about the experience of isolation during the pandemic to explore issues to include factors which improve or worsen the experience of isolation including:

  • The effect of the isolation itself
  • The effect of variations in information provision
  • Concern about infection risk and its variation during the period of "lock-down"
  • Delays to presentation with flare symptoms

Tipo de estudo

Observacional

Inscrição (Antecipado)

232

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Sheffield, Reino Unido, S10 2JF
        • Recrutamento
        • Sheffield Teaching Hospitals NHS FT
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

16 anos e mais velhos (Filho, Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Patients with a clinical diagnosis of IBD who are treated in the clinics of Sheffield Teaching Hosptials NHS FT

Descrição

Inclusion Criteria:

  • IBD Patients who utilise the IBD Clinics at Sheffield Teaching Hospitals NHS FT

Exclusion Criteria:

  • patients who are not part of the IBD clinics at STH NHS FT

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: Coorte
  • Perspectivas de Tempo: Prospectivo

Coortes e Intervenções

Grupo / Coorte
high-risk group
IBD patients who were high risk of infection and were shielding
low-risk group
IBD patients who were low risk of infection and were following standard quarantine guidance
young people from affiliated study
32 IBD patients from an affiliated study

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
What impact has the isolation of patients during social isolation had in terms of psychological morbidity?
Prazo: Changes in psychological morbidity at 12 months
Psychological morbidity will be assessed through the 4 questionnaires
Changes in psychological morbidity at 12 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Have levels of psychological morbidity in young people changed from levels prior to the CoViD pandemic?
Prazo: Changes in psychological morbidity at 12 months
psychological morbidity will be assessed via comparison of questionnaires from affiliated study against the time points of this study
Changes in psychological morbidity at 12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Cadeira de estudo: Alan Lobo, MD, Sheffield Teaching Hospitals NHS FT

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

30 de junho de 2020

Conclusão Primária (Antecipado)

30 de junho de 2022

Conclusão do estudo (Antecipado)

30 de junho de 2022

Datas de inscrição no estudo

Enviado pela primeira vez

24 de julho de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

27 de julho de 2020

Primeira postagem (Real)

28 de julho de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

28 de julho de 2020

Última atualização enviada que atendeu aos critérios de controle de qualidade

27 de julho de 2020

Última verificação

1 de julho de 2020

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • STH21414

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

Não

Descrição do plano IPD

no IPD will be shared with other researchers

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

3
Se inscrever